Natixis’s Castle Biosciences CSTL Stock Holding History

Natixis’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,600	Closed	-$522K	–	1017
2024 Q4	$522K	Buy	+19,600	New	+$597K	﹤0.01%	704

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Natixis's CSTL Position: Q1 2025 in Review

Natixis sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 19,600 shares — an estimated $522K sold.

Natixis first reported a position in CSTL in Q4 2024 and held it in 1 quarter. The position peaked at $522K in Q4 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

Natixis reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
Natixis sold 19,600 Castle Biosciences shares in Q1 2025, an estimated $522K.
Natixis first reported a position in Castle Biosciences in Q4 2024 and held it in 1 quarter.
Natixis's Castle Biosciences position peaked at $522K in Q4 2024.
180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.